Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma (NASDAQ:LUMO) reported its financial results for 2021, ending the year with cash reserves of $94.8 million. The company is progressing with two key clinical trials: the OraGrowtH210, nearing 50% enrollment with expected interim analysis results on height velocity by late 2022, and the OraGrowtH212, also on track for interim analysis. R&D expenses increased by $7 million to $16.2 million, while G&A expenses decreased by $1.9 million to $15.3 million. The net loss grew to $30.4 million in 2021 compared to a loss of $5.7 million in 2020.
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company focused on rare diseases, will participate in two notable conferences in March 2022. The 34th Annual Roth Conference takes place from March 13-15, featuring a live fireside chat on March 14 at 10:30 AM PDT. Additionally, the Maxim 2022 Virtual Growth Conference is scheduled for March 28-30, with a pre-recorded presentation available from March 28 at 9:00 AM EDT. Investors can access the webcasts through Lumos Pharma's website and contact their investor relations for one-on-one meetings.
Lumos Pharma, a clinical-stage biopharmaceutical company (NASDAQ:LUMO), will release its full year 2021 financial results on March 10, 2022, after market close. A conference call to discuss these results and updates on clinical activities will begin at 4:30 PM ET. Investors can join via a live audio webcast or phone. Lumos Pharma is focused on developing therapies for rare diseases, with its lead candidate, LUM-201, aimed at treating Pediatric Growth Hormone Deficiency and currently undergoing clinical trials.
Lumos Pharma (NASDAQ:LUMO) will present at the H.C. Wainwright Virtual BIOCONNECT Conference from January 10-13, 2022. The presentation will be available online starting at 7:00 AM ET on January 10. Interested parties can access the webcast through Lumos Pharma's website under the Investors & Media section and it will be archived for 90 days. Lumos Pharma focuses on developing therapeutics for rare diseases, with its lead candidate LUM-201 targeting Pediatric Growth Hormone Deficiency. LUM-201 is currently undergoing Phase 2 trials and has received Orphan Drug Designation in the US and EU.
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare diseases, will participate in several upcoming investor conferences. At the Stifel 2021 Virtual Healthcare Conference on November 16, Lumos will present from 3:20-3:50 PM EST and hold one-on-one meetings. The Jefferies London Healthcare Conference, running from November 16 to 19, will feature a pre-recorded chat available November 18. Additionally, Lumos will engage at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, with a fireside chat available from November 22.
Lumos Pharma, focused on therapeutics for rare diseases, reported its Q3 2021 financial results. The company continues to advance its LUM-201 program for pediatric growth hormone deficiency (PGHD) with major progress in its OraGrowtH210 trial. With cash reserves of $100.7 million, operations are funded through critical data readouts anticipated in 2H 2023. R&D expenses rose to $4.1 million, primarily due to clinical trial costs, while general expenses dropped to $3.4 million. The net loss for Q3 2021 was $7.5 million, contrasting with a net gain of $1.8 million in Q3 2020.
Lumos Pharma, Inc. (LUMO) will announce its Q3 2021 financial results on November 3, 2021, after market close. A conference call is scheduled for 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. The public can access the live webcast via a dedicated link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its leading candidate, LUM-201, undergoing Phase 2 trials for Pediatric Growth Hormone Deficiency.
Lumos Pharma, a clinical-stage biopharmaceutical company, will participate in two major conferences in September. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, featuring a pre-recorded presentation available from September 13 at 7:00 AM ET. Additionally, the Cantor Virtual Global Healthcare Conference is scheduled for September 27-30, with a live fireside chat on September 29 from 4:00-4:30 PM ET. Lumos Pharma focuses on developing therapeutics for rare diseases, including its lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency.
Lumos Pharma has announced key leadership changes, promoting John McKew to President and appointing David B. Karpf as Chief Medical Officer. The company reported a Q2 2021 net loss of $8.7 million, up from $5.4 million in Q2 2020, with cash reserves growing to $107.7 million. The OraGrowtH210 Trial's primary data outcome has been extended to late 2023 due to COVID-related delays. The initiation of the OraGrowtH212 Trial is also noted, alongside efforts to assess LUM-201's potential for further indications in rare diseases.
Lumos Pharma (NASDAQ:LUMO) recently appointed Dr. David B. Karpf as Chief Medical Officer, effective August 3, 2021. Dr. Karpf brings over 35 years of clinical endocrinology experience and extensive knowledge in biopharmaceutical development, previously serving as Vice President of Clinical Development at Ascendis Pharma. He has been involved in significant clinical advancements, including LUM-201, Lumos Pharma's oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently undergoing Phase 2 trials. His expertise is expected to significantly enhance Lumos Pharma's clinical capabilities.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
